Bharat Biotech receives DCGI approval for Phase 3 clinical trials of its Intra-Nasal vaccine

Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country. Bharat Biotech on Friday received approval from Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials for its BBV 154 Nasal COVID vaccine. The trials will evaluate the efficacy of nasal vaccine for those vaccinated with the primary two doses of COVID vaccines (Covishield and Covaxin). Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country. Hyderabad-based Bharat Biotech had asked for DCGI

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!